The economic evaluation of the HPTN071/PopART study
How to cite
Hauck, Katharina. 2022. "The economic evaluation of the HPTN071/PopART study." AEA RCT Registry. AEARCTR-0008789. https://doi.org/10.1257/rct.8789-1.0
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
HPTN071/PopART is a community randomized trial that is investigating whether a community-wide combination HIV prevention package including annual home-based HIV testing, active referral and the offer of immediate ART for those testing HIV-positive, along with the promotion of proven HIV prevention methods (such as voluntary medical male circumcision and condom use), will help to prevent transmission and substantially reduce new HIV infections. The study was conducted in 21 communities in Zambia and South Africa (randomized into 3 arms, each with 7 communities) with a total population of approximately 1.2 million individuals. The economic evaluation of the HPTN071/PopART trial is a secondary outcome of the study. It's objective is to determine the societal value of the trial with a cost-effectiveness analysis that compares the incremental benefits and costs of the PopART intervention against enhanced standard of HIV care in the study communities. The economic evaluation also analyses the impact of the intervention on other economic outcomes, including work productivity, inequality in incomes and access to healthcare, and impact on health-related quality-of-life.
Intervention
Arm A:
Universal Testing with Immediate Anti-retroviral therapy (ART)
Other: Universal Testing with immediate ART
Combination prevention package including: House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units
Arm B:
ART according to National Guidelines
Other: Universal Testing with ART eligibility according to National Guidelines
Combination prevention package including: House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units.
Arm C:
Standard of Care
Includes: Strengthening of HIV testing and ART services according to national guidelines at health facilities and other venues; Strengthening of male circumcision and PMTCT services available at health facilities and other venues in the community; and Treatment of STIs and provision of condoms at health facilities and other venues in the community.
Experimental design
The trial was conducted from 2014 through 2018, in 21 urban or periurban communities in Zambia and Western Cape Province, South Africa (total population, approximately 1 million; mean, approximately 50,000 per community). Each community was the catchment population of a government clinic. Communities were grouped in seven triplets matched on the basis of geographic location and estimated HIV prevalence. Communities in each triplet were randomly assigned to three trial groups in simultaneous public ceremonies. Restricted randomization was used to ensure balance across the trial groups with respect to population size, baseline ART coverage (the percentage of HIV-positive persons who were receiving ART), and HIV prevalence. Randomization and locations of the trial communities are shown in the supplement of Hayes et al (2019), available at https://www.nejm.org/doi/full/10.1056/NEJMoa1814556. Group A communities received a combination prevention intervention (described below) with universal ART. Group B communities received a combination prevention intervention with ART provided according to local guidelines. Group C communities did not receive a combination prevention intervention but received standard care at government clinics, including HIV testing and ART offered according to local guidelines.
The combination prevention intervention was delivered to group A and B communities. Specially trained community health workers (community HIV-care providers) delivered services at annual household visits (see the Supplementary Appendix). The community health workers worked in pairs, with each pair responsible for approximately 500 households. Data that were collected by the community health workers were used primarily to support service delivery but also to evaluate intervention coverage. At each visit, the community health workers offered HIV counseling and rapid testing, and they provided support for linkage to care and ART adherence for HIV-positive clients. They referred uncircumcised HIV-negative men for voluntary medical male circumcision and referred HIV-positive pregnant women for antenatal care, including prevention of mother-to-child HIV transmission. The community health workers also screened clients for symptoms of tuberculosis and sexually transmitted infections, with referral for diagnosis and treatment, and promoted and provided condoms. In all 21 communities, HIV care and ART were provided at local government clinics. In group A, these clinics offered ART irrespective of CD4 cell count throughout the trial, with written consent for patients initiating ART outside local guidelines until universal ART became standard. In groups B and C, the clinics provided ART initially at a CD4 threshold of 350 cells per microliter, which increased to 500 cells per microliter in 2014. Universal ART was offered from April 2016 onward (in Zambia) and October 2016 onward (in South Africa).
Design details
Cited by
No citation data available for this registration yet.